海外の治験の状況「%E8%84%B3%E5%8D%92%E4%B8%AD」での検索結果
55件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- Study to determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients who have been newly diagnosed with multiple myeloma and have not received previous anti-myeloma treatment
- Newly diagnosed multiple myeloma MedDRA version: 18.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Belgium, Canada, France, United States
- 2013-04-22
Authorised
- Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients with mild Alzheimer's Disease (STEADFAST)
- MILD ALZHEIMER'S DISEASE RECEIVING ACETYLCHOLINESTERASE INHIBITORS AND/OR MEMANTINE MedDRA version: 20.0 Level: PT Classification code 10012271 Term: Dementia Alzheimer's type System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: HLT Classification code 10001897 Term: Alzheimer's disease (incl subtypes) System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: HLT Classification code 10012268 Term: Dementia (excl Alzheimer's type) System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10012296 Term: Dementia of the Alzheimer's type, with depressed mood System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10012295 Term: Dementia of the Alzheimer's type, with delusions System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10012294 Term: Dementia of the Alzheimer's type, with delirium System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10012293 Term: Dementia of the Alzheimer's type, uncomplicated System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: LLT Classification code 10012292 Term: Dementia of the Alzheimer's type NOS System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: LLT Classification code 10066571 Term: Progression of Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Australia, Canada, Ireland, New Zealand, South Africa, United Kingdom, United States
- 2016-06-07
Authorised
- The research study for patients with Alzheimer's disease to examine the safety and efficacy of Pimavanserin for the treatment of symptoms of agitation and aggression
- Agitation and Aggression in Alzheimer's Disease MedDRA version: 19.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Chile, France, Germany, Spain, United Kingdom, United States
- 2016-12-27
Authorised
- A Phase 1/2 Open-label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102
- Arginase 1 deficiency Hyperargininemia MedDRA version: 20.0 Level: PT Classification code 10062695 Term: Arginase deficiency System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Canada, Portugal, United Kingdom, United States
- 2018-01-12
Authorised
- An open-label extension study evaluating the safety and tolerability of leuco-methylthioninium dihydromesylate (LMTM) in subjects with Alzheimer's Disease or a rare form of dementia (Behavioral Variant Frontotemporal Dementia) who have completed an earlier Phase trial
- Alzheimer’s Disease and behavioral variant Frontotemporal Dementia MedDRA version: 19.0 Level: PT Classification code 10068968 Term: Frontotemporal dementia System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Australia, Belgium, Bulgaria, Canada, Croatia, Finland, France, Germany, Korea, Republic of, Malaysia, Netherlands, Romania, Russian Federation, Singapore, Spain, Taiwan, United Kingdom, United States
- 2014-08-20
Authorised
- DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL- TO-MILD ALZHEIMER’S DISEASE
- Alzheimer’s Disease (AD) MedDRA version: 20.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Australia, Austria, Belgium, Bulgaria, Canada, Costa Rica, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Lithuania, Mexico, Poland, Portugal, Russian Federation, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, United States
- 2016-05-26
Authorised
- A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects with Mild Alzheimer’s Disease
- Alzheimer's Disease MedDRA version: 20.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Czech Republic, Denmark, Netherlands, United Kingdom, United States
- 2018-03-08
Authorised
- A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects with Mild Alzheimer’s Disease
- Alzheimer's Disease MedDRA version: 20.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Czech Republic, Denmark, Netherlands, United Kingdom, United States
- 2018-02-21
Authorised
- A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects with Mild Alzheimer’s Disease
- Alzheimer's Disease MedDRA version: 20.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Czech Republic, Denmark, Netherlands, United Kingdom, United States
- 2018-02-01
Authorised
- A phase III Safety and Efficacy Study of ALZT-OP1 in Subjects with Evidence of Early Alzheimer’s Disease.
- Early stage of Alzheimer's Disease. MedDRA version: 20.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
- Australia, Bulgaria, Czech Republic, Hungary, Poland, Romania, United States
- 2015-10-06
